Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
The hydroxymethylglutaryl-coenzyme A reductase inhibitors (HMG-CoAs) are one of the most significant causes of medication induced rhabdomyolysis. The development of rhabdomyolysis is increased when the HMG-CoAs are used concurrently with certain other medications, specifically gemfibrozil and macrolide antibiotics. In this report, we describe a patient with rhabdomyolysis from the combined use of lovastatin, gemfibrozil, and clarithromycin and review the relevant literature.
Landesman
K A
KA
Brown University School of Medicine, Internal Medicine Residency Program Providence, Rhode Island, USA.
Stozek
M
M
Freeman
N J
NJ
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D015248:Gemfibrozil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008148:Lovastatin / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced*
D000900:Anti-Bacterial Agents; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008148:Lovastatin; D017291:Clarithromycin; D015248:Gemfibrozil